Balanced news tone
News Sentiment
IMRN sentiment intelligence
Immuron Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+11.8% over one week, +3.4% over four weeks, trend active, and below fair value.
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3
Immuron Ltd Chief Commercial Officer Flavio Palumbo has filed an initial ownership report (Form 3) disclosing his equity interests in the company. The filing indicates he directly holds 1,142,909 Ordinary Shares and 640,824 Performance Rights. These Performance Rights have a zero
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 20:10
- Source
- Stock Titan
Immuron (IMRN) director discloses shareholdings and long-dated options
Immuron Ltd director Daniel Jude Pollock has filed an initial Form 3, disclosing his direct ownership of 568,750 Ordinary Shares and indirect ownership of 174,480 Ordinary Shares through joint ownership with his spouse. The filing also reveals his holdings of options over 1,000,0
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 20:10
- Source
- Stock Titan
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Immuron Ltd IMRN
This page provides an overview of Immuron Ltd (IMRN) stock, showing its current trading price, market capitalization, and recent performance. The stock is trading at $0.880, up 9.86%, with a market cap of $5.15M. The page includes sections for financials, discussions, and analysi
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 13 May 2026 08:39
- Source
- TradingKey
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Immuron (IMRN) Sees Impressive Sales Surge for Travelan in FY25
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jul 2025 07:00
- Source
- GuruFocus
Immuron (IMRN) Stock Forecast and Price Target 2026
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 19 May 2024 11:12
- Source
- MarketBeat
Immuron Limited (IMRN) Stock Forecast & Price Prediction 2026–2030
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 06 Apr 2023 12:50
- Source
- CoinCodex
Immuron Stock Price Forecast. Should You Buy IMRN?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 08 Dec 2020 12:28
- Source
- StockInvest.us
Should I buy IMMURON (IMRN)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jun 2017 19:45
- Source
- Zacks Investment Research